Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.40
AGN's Cash-to-Debt is ranked lower than
76% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. AGN: 0.40 )
Ranked among companies with meaningful Cash-to-Debt only.
AGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.42 Max: 32.29
Current: 0.4
0.02
32.29
Equity-to-Asset 0.59
AGN's Equity-to-Asset is ranked lower than
56% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. AGN: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
AGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.63 Max: 0.9
Current: 0.59
0.27
0.9
Piotroski F-Score: 6
Altman Z-Score: 1.28
Beneish M-Score: -2.01
WACC vs ROIC
6.60%
-0.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -12.08
AGN's Operating Margin % is ranked lower than
79% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. AGN: -12.08 )
Ranked among companies with meaningful Operating Margin % only.
AGN' s Operating Margin % Range Over the Past 10 Years
Min: -54.9  Med: 6.95 Max: 14.13
Current: -12.08
-54.9
14.13
Net Margin % 100.04
AGN's Net Margin % is ranked higher than
99% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. AGN: 100.04 )
Ranked among companies with meaningful Net Margin % only.
AGN' s Net Margin % Range Over the Past 10 Years
Min: -34.87  Med: 5.67 Max: 102.76
Current: 100.04
-34.87
102.76
ROE % 18.53
AGN's ROE % is ranked higher than
81% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. AGN: 18.53 )
Ranked among companies with meaningful ROE % only.
AGN' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 18.53
-11.23
19.24
ROA % 11.06
AGN's ROA % is ranked higher than
80% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. AGN: 11.06 )
Ranked among companies with meaningful ROA % only.
AGN' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 11.31
Current: 11.06
-4.32
11.31
ROC (Joel Greenblatt) % -58.17
AGN's ROC (Joel Greenblatt) % is ranked lower than
80% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. AGN: -58.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -112.05  Med: 20.42 Max: 38.44
Current: -58.17
-112.05
38.44
3-Year Revenue Growth Rate 27.40
AGN's 3-Year Revenue Growth Rate is ranked higher than
90% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. AGN: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 17.5 Max: 40.4
Current: 27.4
-16.3
40.4
3-Year EBITDA Growth Rate 41.70
AGN's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. AGN: 41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 13.1 Max: 67.4
Current: 41.7
-47.7
67.4
3-Year EPS without NRI Growth Rate -1.20
AGN's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AGN: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 5.4 Max: 94.3
Current: -1.2
-27.1
94.3
GuruFocus has detected 6 Warning Signs with Allergan PLC $AGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AGN Guru Trades in Q2 2016

Jeff Auxier 1,050 sh (New)
John Burbank 708,071 sh (New)
Robert Bruce 25,000 sh (New)
Carl Icahn 3,400,000 sh (New)
David Tepper 1,260,809 sh (+351.73%)
Jerome Dodson 102,000 sh (+155.00%)
Alan Fournier 1,171,614 sh (+134.32%)
Wallace Weitz 595,961 sh (+95.58%)
Mario Gabelli 60,913 sh (+53.06%)
RS Investment Management 489,611 sh (+48.10%)
Joel Greenblatt 20,529 sh (+42.89%)
Scott Black 6,365 sh (+29.77%)
Pioneer Investments 888,950 sh (+26.87%)
Leon Cooperman 671,212 sh (+19.59%)
Seth Klarman 2,001,978 sh (+16.29%)
David Carlson 430,000 sh (+16.22%)
Ken Fisher 3,594 sh (+11.44%)
Paul Singer 2,735,000 sh (+9.53%)
Vanguard Health Care Fund 12,066,307 sh (+7.85%)
Diamond Hill Capital 62,502 sh (+2.93%)
Daniel Loeb 500,000 sh (unchged)
John Burbank 90,000 sh (unchged)
Alan Fournier 1,100,000 sh (unchged)
Louis Moore Bacon 12,000 sh (unchged)
Paul Singer 3,000,300 sh (unchged)
John Paulson 214,700 sh (unchged)
Bernard Horn 17,389 sh (unchged)
John Hussman Sold Out
First Eagle Investment Sold Out
Jeremy Grantham Sold Out
Jana Partners Sold Out
Eric Mindich Sold Out
Steve Mandel Sold Out
David Einhorn Sold Out
Daniel Loeb 4,900,000 sh (-2.00%)
Private Capital 137,319 sh (-15.09%)
John Paulson 3,948,451 sh (-27.13%)
Lee Ainslie 878,319 sh (-37.72%)
George Soros 80,735 sh (-43.65%)
Ron Baron 13,923 sh (-48.96%)
John Griffin 700,900 sh (-53.36%)
Andreas Halvorsen 1,939,703 sh (-60.27%)
Paul Tudor Jones 34,942 sh (-65.23%)
Ruane Cunniff 3,435 sh (-99.67%)
Eaton Vance Worldwide Health Sciences Fund 273,025 sh (-19.94%)
» More
Q3 2016

AGN Guru Trades in Q3 2016

Manning & Napier Advisors, Inc 10,510 sh (New)
Tom Gayner 2,000 sh (New)
Jeff Auxier 6,750 sh (+542.86%)
John Griffin 1,259,200 sh (+79.65%)
Ron Baron 17,109 sh (+22.88%)
Ken Fisher 4,024 sh (+11.96%)
Pioneer Investments 982,212 sh (+10.49%)
Signature Select Canadian Fund 36,100 sh (+5.25%)
David Carlson 450,000 sh (+4.65%)
Jerome Dodson 104,500 sh (+2.45%)
Wallace Weitz 609,963 sh (+2.35%)
Scott Black 6,405 sh (+0.63%)
Eaton Vance Worldwide Health Sciences Fund 350,880 sh (+28.52%)
Louis Moore Bacon 12,000 sh (unchged)
Alan Fournier 1,100,000 sh (unchged)
Seth Klarman 2,001,978 sh (unchged)
Paul Singer 2,735,000 sh (unchged)
Paul Singer 2,099,700 sh (unchged)
George Soros 80,735 sh (unchged)
John Paulson 214,700 sh (unchged)
Robert Bruce 25,000 sh (unchged)
Bernard Horn 17,389 sh (unchged)
Lee Ainslie Sold Out
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
Vanguard Health Care Fund 11,917,739 sh (-1.23%)
John Paulson 3,891,134 sh (-1.45%)
Private Capital 134,667 sh (-1.93%)
David Tepper 1,218,309 sh (-3.37%)
Mario Gabelli 55,988 sh (-8.09%)
Ruane Cunniff 3,075 sh (-10.48%)
Diamond Hill Capital 52,179 sh (-16.52%)
Leon Cooperman 541,122 sh (-19.38%)
Paul Tudor Jones 27,428 sh (-21.50%)
Daniel Loeb 3,785,000 sh (-22.76%)
Alan Fournier 621,214 sh (-46.98%)
John Burbank 375,134 sh (-47.02%)
Carl Icahn 425,438 sh (-87.49%)
» More
Q4 2016

AGN Guru Trades in Q4 2016

First Eagle Investment 26,600 sh (New)
First Pacific Advisors 16,500 sh (New)
Steven Cohen 84,101 sh (New)
NWQ Managers 280,596 sh (New)
Joel Greenblatt 116,791 sh (New)
Tom Gayner 14,000 sh (+600.00%)
David Tepper 4,261,406 sh (+249.78%)
Seth Klarman 3,432,603 sh (+71.46%)
Jerome Dodson 170,000 sh (+62.68%)
Scott Black 8,147 sh (+27.20%)
Pioneer Investments 1,229,649 sh (+25.19%)
Mario Gabelli 68,848 sh (+22.97%)
John Griffin 1,539,500 sh (+22.26%)
Jeff Auxier 7,840 sh (+16.15%)
Paul Tudor Jones 31,400 sh (+14.48%)
Private Capital 149,819 sh (+11.25%)
Vanguard Health Care Fund 12,649,139 sh (+6.14%)
Wallace Weitz 637,733 sh (+4.55%)
Diamond Hill Capital 53,883 sh (+3.27%)
Ken Fisher 4,048 sh (+0.60%)
David Carlson 450,000 sh (unchged)
Robert Bruce 25,000 sh (unchged)
Paul Singer 2,735,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Carl Icahn 425,438 sh (unchged)
John Paulson 214,700 sh (unchged)
Bernard Horn 17,389 sh (unchged)
Daniel Loeb Sold Out
Ruane Cunniff Sold Out
John Burbank Sold Out
Alan Fournier Sold Out
George Soros 77,135 sh (-4.46%)
Manning & Napier Advisors, Inc 9,880 sh (-5.99%)
John Paulson 3,554,734 sh (-8.65%)
Ron Baron 14,572 sh (-14.83%)
Leon Cooperman 363,788 sh (-32.77%)
Eaton Vance Worldwide Health Sciences Fund 321,548 sh (-8.36%)
» More
Q1 2017

AGN Guru Trades in Q1 2017

Manning & Napier Advisors, Inc 11,980 sh (+21.26%)
Jerome Dodson 177,000 sh (+4.12%)
Spiros Segalas 1,513,884 sh (-38.15%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA844.946.515 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:SGIOY, OTCPK:ESALF, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:PRGO, OTCPK:APNHF, OTCPK:IPSEY, OTCPK:ORINY, NYSE:RDY, OTCPK:HYPMY, OTCPK:HKMPF, NYSE:TARO, NYSE:MNK, NAS:OPK » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan is one of the largest specialty pharmaceutical manufacturers. Allergan specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Guru Investment Theses on Allergan PLC

Weitz Funds Comments on Allergan - Jan 26, 2017

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be a prudent use of excess cash in the long run. Future capital deployment and late-stage pipeline success remain potential positives over the next 12 -24 months. We continue to believe Allergan shares present compelling value at current prices.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Allergan - Nov 11, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. One week after closing the sale of Actavis generics to Teva Pharmaceuticals, Allergan reported mildly disappointing top-line results for the quarter. Importantly, however, Allergan’s “core” products continue to grow nicely, with five of the company’s seven core therapeutic categories growing by double digits (in constant currency) versus the prior year. Our base case valuation of $350-360 per share does not depend on Allergan hitting CEO Brent Saunders’ goal of double- digit organic growth. However, strong, high single-digit organic sales growth appears achievable, as the company’s recently launched products continue to scale. One near-term positive of a lower share price is that Allergan’s $5 billion in share repurchases between now and year end will go further, and deployment of a portion of the company’s nearly $28 billion in cash remains a possible catalyst for the stock. The re-emergence of drug pricing as a political issue is not surprising to us as we enter the home stretch of the presidential election. We believe Secretary Clinton’s plan to control and eventually lower prescription drugs costs could negatively impact Allergan’s long-term earnings trajectory (perhaps by $2-3 per share on a base of $18), should she win the election, but with the stock at $240, we believe the risk of permanent loss is low. In short, Allergan’s risk/reward ratio (upside to base case vs. downside to low case) continues to be skewed in favor of the long-term owner.





  • From Weitz Balanced Fund third quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Daniel Loeb Comments on Akarna Therapeutics - Nov 02, 2016

Akarna Therapeutics TPV was a founding investor in Akarna in Q1 2015. Akarna focuses on the treatment of Nonalcoholic Steatohepatitis (NASH), also known as fatty liver disease. Akarna was attractive for several reasons:



  • Large market opportunity: Epidemiologic studies suggest that NASH affects 2 – 5% of Americans and is believed to be correlated with increasing rates of obesity, diabetes, and high cholesterol. If left untreated, NASH can lead to liver fibrosis, cirrhosis, and, ultimately, end-stage liver disease. Unfortunately, there are no currently approved treatments for NASH.

  • Derisked mechanism of action: Clinical trials with bile acids have validated farnesoid X receptor agonists as a viable therapeutic agent based on clinical and histological biomarkers of the disease. These trials have also demonstrated a clear need for treatments with still improved efficacy and better side effect profiles.

  • Active area of business development: Over the past few years, the sector has seen burgeoning interest in NASH assets with partnerships or acquisitions (e.g., Gilead / Nimbus, Merck / NGM) occurring at attractive valuations.

The team at Akarna identified a potentially best-in-class lead candidate with an attractive pre-clinical profile in in vitro and animal studies. Akarna also secured a broad intellectual property portfolio around the lead compound family.



In August 2016, just 18 months after Akarna was founded, Allergan acquired the company for an upfront payment of $50 million and undisclosed potential clinical, regulatory, and commercial milestones. For Third Point Ventures, our share of the upfront payment reflects a total return of 3.1x our initial investment. If Allergan (NYSE:AGN) successfully develops and commercializes the Akarna drug, the total return on our investment could be meaningfully larger.



From Third Point's third-quarter 2016 commentary.



Check out Daniel Loeb latest stock trades

Jerome Dodson Comments on Allergan - Jul 26, 2016

Allergan (NYSE:AGN), an innovative pharmaceutical company best known for developing Botox, reduced the return by 41 basis points as the stock dropped 13.8% from $268.03 to $231.09. The shares sank after Pfizer terminated its plans to acquire Allergan for $160 billion. Pfizer walked away from the deal because of new rules from the U.S. Treasury that prevent tax-lowering corporate inversions. We used the stock’s weakness to increase our position, since Allergan has an attractive collection of durable brands. We also like the fact that the company is in the process of selling its generic drug unit to Teva for $40 billion, which will enable Allergan to repurchase stock, pay down debt and acquire innovative drug companies.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

Weitz Funds Comments on Allergan - Jul 20, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. The dissolution of Allergan’s merger with Pfizer in April, delays in gaining Federal Trade Commission approval for the sale of its global generics business to TEVA and broader industry concern around prescription drug prices combined to push Allergan’s stock down by 26% during the first half of the calendar year. As we wrote in January, we like the stand-alone Allergan business without the generics business and believe the $ 40 billion sale to TEVA should soon close. There are a number of signs that growth in Allergan’s aesthetics franchise is accelerating, and the company’s key product launches – VIBERZI, VRAYLAR and KYBELLA – appear to be off to healthy starts. The combination of healthy organic growth, debt reduction and meaningful share repurchases should drive per share value creation over our investment horizon. We substantially increased the Fund’s Allergan position during the second quarter at attractive discounts to our business value estimate.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Ruane Cunniff Comments on Allergan - Jul 13, 2016

We exited two smaller positions during the quarter. While Allergan (NYSE:AGN) has a stronger collection of assets and far better outlook than Valeant, we suspect many drug makers will face increasing pressure from health care payers who need to reduce the relentless double-digit inflation rate for branded pharmaceuticals.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund second quarter 2016 shareholder letter.

Check out Ruane Cunniff latest stock trades

Baron Funds Comments on Allergan plc - May 06, 2016

Our conviction to buy Allergan plc (NYSE:AGN) in the first quarter relied on differentiation of Allergan from its specialty pharmaceutical peers (Valeant, Endo, Mallinckrodt) given the quality of its asset mix (Botox, glaucoma drugs, breast implants, aesthetics, etc.) and its non-reliance on distasteful price increases for growth. Admittedly, we were aware of the potential upside to the Pfizer deal and were disappointed with the Treasury’s actions to stem tax inversions. Regardless, we were comfortable with Allergan as a stand-alone company, given the above base business married to the pending closure of the sale of Allergan’s generics portfolio to Teva for approximately $40 billion. This deal (pending over the next quarters) will help drive Allergan’s M&A efforts towards obtaining a more biotech like growth profile, which should both drive increases in top/bottom-line growth and expand the multiple at which investors are willing to value Allergan’s business. However, while our initial thesis remains intact, the entire specialty pharmaceutical space has re-rated given the above-mentioned bad actors. This has pressured the entire space, and we decided to exit specialty pharmaceuticals and focus on the more innovative biotech space going forward.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Apr 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focused on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter pharmaceutical products. A combination of factors contributed to the decline in Allergan’s stock during the quarter, including continued discussions of potential drug price regulation, regulatory delays in closing the company’s sale of its generic drug operations to TEVA and uncertainty around the viability of the proposed merger with Pfizer (which, subsequent to quarter end, has officially been called off). We believe the risk of the TEVA transaction falling through is low, and the company’s collection of durable growth assets, management acumen and balance sheet optionality create multiple paths for durable shareholder value creation in the years ahead. We added to our position during the quarter.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Bernard Horn Comments on Allergan PLC - Mar 21, 2016

In healthcare, pharmaceutical maker Allergan PLC (NYSE:AGN) was expected to achieve 80% of an estimated $1.8 billion in synergies stemming from recent acquisitions by the end of the first quarter of 2016. With valuable drugs like Botox and a rich R&D pipeline, Allergan was approached by Pfizer. Pfizer held preliminary and friendly discussions to acquire Allergan, which will offer Pfizer a low tax domicile in Dublin.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

GAMCO Global Growth Fund Comments on Allergan Plc - Feb 22, 2016

Allergan plc (NYSE:AGN) (3.4% of net assets as of December 31, 2015) (AGN – $312.50 – NYSE) markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. A combination with Pfizer is pending and should close sometime this year.





From the GAMCO Global Growth Fund fourth quarter 2015 commentary.



Check out Mario Gabelli latest stock trades

Baron Funds Comments on Allergan - Jan 27, 2016

Allergan plc (NYSE:AGN) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing brand, generic and biosimilar products. Probably best known for its Botox, Allergan has undergone a massive, M&A driven transformation after combinations with Forest Labs ($25 billion) and Actavis ($66 billion) have created a $120 billion behemoth. In the process, the company has upgraded its quality of earnings and diversified away from legacy dermatology and ophthalmology businesses. Our analysis suggested that Allergan’s earnings could rise from about $15/share this year, to about $25/share in five years making it attractive enough to initiate a small position. Late in the fourth quarter, Pfizer made a long speculated cash and stock bid to acquire Allergan at about a 20% premium to its price. So-called “tax inversion” is one of the goals analysts believe Pfizer was after in attempting to acquire Allergan, and various U.S. politicians have spoken out about the need to try and prevent these kinds of transactions. We believe Allergan should do well regardless of whether this deal will go through or not (although, we think that it will) as the stock did not move and continues to trade at about 20% discount to Pfizer’s offer price.



From the Baron Fifth Avenue Growth Fund Fourth Quarter 2015 Letter.



Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Jan 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.



From the Weitz Funds' Research Fund shareholder letter for fourth quarter 2015.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Jan 22, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Oct 27, 2015

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Formerly Actavis, the “new” Allergan is a collection of significant acquisitions over the past 4-5 years, including Watson Pharmaceuticals, Warner Chilcott, Forest Laboratories and legacy Allergan. In late July, Allergan announced the divestiture of its global generics business to Teva for $40.5B, which we believe is a terrific sale price for AGN. Assuming the transaction closes as expected, Allergan should begin calendar 2016 as a pure-play branded pharmaceutical manufacturer with high single digit annual growth prospects and a reloaded balance sheet. We believe the stock is compelling at current prices.



From Wallace Weitz (Trades, Portfolio)'s 3Q 2015 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Allergan PLC

Valeant: It's Not a Game of Chess – Part IV A case study of the company's rise and fall
The key to Valeant’s business model was its acquisition strategy. Valeant used the following parameters to guide investors on its acquisition criteria: Read more...
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne

Program on Track for FDA Submission in the Second Half of 2017

DUBLIN, Ireland and BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- Allergan plc, (:AGN), a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two (2) Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy endpoints. Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting.  Based on these data, Allergan plans to file a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) in the second half of this year.  “The positive efficacy results observed in the pivotal phase 3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne,” said David Nicholson, Chief Global Research & Development Officer at Allergan. “We look forward to submitting a new drug application for sarecycline and bringing to market a potential new option for physicians treating patients with acne.”  “We are pleased with the results of the sarecycline Phase 3 program and Allergan’s intention to move ahead with an NDA submission for approval in the U.S. by the end of 2017,” said Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer, Paratek.  â€œSarecycline is a narrow spectrum antibiotic, which we believe can offer meaningful clinical benefits for patients afflicted with acne.”   About SC1401 and SC1402
Both SC1401 & SC1402 were designed to be replicative phase 3 randomized, multicenter, double-blind, placebo-controlled studies to evaluate the efficacy and safety of 1.5 mg/kg per day of sarecycline compared to placebo in the treatment of moderate to severe acne. The primary objective was to evaluate the efficacy and safety of oral sarecycline 1.5 mg/kg per day compared to placebo in treating inflammatory acne lesions in subjects with moderate to severe acne based on Investigators Global Assessment (IGA) scale score and inflammatory lesion counts. Patients were randomized (1:1) into two treatment groups to receive either sarecycline tablets (60 mg, 100 mg and 150 mg, providing a dose of 1.5 mg/kg/day) or placebo once a day for 12 weeks. Sarecycline was statistically significantly (p < 0.004) superior to placebo with respect to primary efficacy endpoints. The most common adverse events (>2%) reported in the sarecycline group were nausea (3.2%), nasopharyngitis (2.8%), and headache (2.8%). The rate of discontinuation due to adverse events among sarecycline-treated patients in the two studies combined was 1.4%. About Allergan plc Allergan plc (:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70 mid-to-late stage pipeline programs in development. Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right. With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day. For more information, visit Allergan's website at www.Allergan.com. About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin structure infections (ABSSSI) demonstrating the efficacy and safety of intravenous (IV) to once-daily oral omadacycline compared to linezolid.  A Phase 3 registration study for community-acquired bacterial pneumonia (CABP) comparing IV-to-once-daily oral omadacycline to IV-to-oral moxifloxacin was initiated in November 2015 and completed enrollment in January 2017. Paratek will report top-line data from this study early in the second quarter of 2017. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016.  Top-line data from this study are expected as early as the second quarter of 2017.  A Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016 and positive top-line PK proof-of-principle data were reported in November 2016.  The company plans to begin enrolling patients in a proof-of-concept Phase 2 study in complicated UTI as early as the fourth quarter of 2017. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for several indications. In October 2016, Paratek announced a new cooperative research effort with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to study omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance. These studies are designed to confirm dosing regimens and assess efficacy of omadacycline against biodefense pathogens, including Yersinia pestis (plague) and Bacillus anthracis (anthrax). Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting.  Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights.  For more information, visit www.paratekpharma.com.  Forward Looking Statements
This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical trials, prospects and expected results, including statements about the timing of advancing the clinical and regulatory program for sarecycline.  All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to (i) our need for substantial additional funding to complete the development and commercialization of our product candidates, (ii) our ability to raise the capital to do so, (iii) our ability to develop our drug candidates for potential commercialization, (iv) the advancement of omadacycline Phase 3 trials for ABSSSI and CABP, (v) the potential for omadacycline to be successfully developed for use as a first-line empiric monotherapy for patients suffering from serious community-acquired bacterial infections, (vi) the potential of omadacycline to become the primary antibiotic choice of physicians for the treatment of serious community-acquired bacterial infections, (vii) the ability of our supply chain to provide adequate supply to satisfy our clinical and commercial demand (viii) the potential use and effectiveness of sarecycline for the treatment of acne and rosacea in the community setting, and (ix) risks that sarecycline data to date and trends may not be predictive of future results, risks related to the conduct of our clinical trials, and risks that our clinical trials and product candidates do not receive regulatory approval.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2015, and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein. Allergan Forward-Looking Statement Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:

PARATEK:
Media:
Michael Lampe
Scient Public Relations
(484) 575-5040
[email protected]

Investors:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

ALLERGAN:
Media:
Mark Marmur
862-261-7558

Investors:
Karina Calzadilla
862-261-7558

Read more...
The Most Attractive Value Stock There Is? These value investors love Allergan
Of all the data contained in hedge fund 13F filings published over the past few weeks for trading activity conducted during the last quarter of 2016, there is one trend that really stands out. Read more...
Share Buybacks Decline for Second Straight Year in 2016 Buffett's Apple makes second biggest repurchase; dividends on the rise
According to S&P Dow Jones Indices, companies of the S&P 500 index in the fourth quarter pulled back on their share repurchases by 7.2% from the fourth quarter 2015, although they accelerated 20.6% sequentially. Read more...
Scott Black Continues to Buy Allergan, CVS Health, 6 Others The guru bought these stakes in the 3rd and 4th quarters
Scott Black (Trades, Portfolio) is the chairman, president, chief investment officer and chief compliance officer at Delphi Management Inc. He manages a portfolio composed of 93 stocks with a total value of $171 million. In the third and fourth quarters of 2016 the guru bought shares in the following stocks: Read more...
Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

– Brings Together Eye Care and CRISPR Innovators to Develop Transformative Medicines for Patients – – Provides Allergan Exclusive Access to Multiple Editas Medicine Ocular Programs Based on its Unparalleled CRISPR Genome Editing Platform – – Reinforces Allergan’s Continued Commitment to Developing Innovative Treatments for Unmet Needs in Eye Care – DUBLIN, Ireland and CAMBRIDGE, Mass., March 14, 2017 (GLOBE NEWSWIRE) -- Allergan plc (:AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in pre-clinical development. The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being developed for the potential treatment of LCA10, a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness. “The CRISPR genome editing platform holds the potential to transform the treatment of many genetic and non-genetically derived diseases, including diseases and conditions of the eye,” said David Nicholson, Chief Research and Development Officer, Allergan. “The Allergan team is excited to work with colleagues at Editas Medicine to develop and potentially deliver game-changing treatment for retinal diseases like LCA10. This program is highly complementary to our ongoing eye care development programs where unmet medical need exists for patients.” “Allergan has long been a leader in advancing innovative therapies to treat eye diseases,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine.  “Working together with Allergan through their Open Science R&D model significantly enhances our ability to develop genome editing medicines to help patients with serious eye diseases. This alliance is highly aligned with our strategy to build our company for the long-term and to realize the broad potential of our genome editing platform to treat serious diseases.” CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a dynamic, versatile tool that can be programmed to target specific stretches of genetic code and edit DNA at precise locations in the human genome. The technology allows researchers to permanently modify genes and has the potential to create medicines with a durable treatment effect. Under the terms of the agreement, Editas Medicine will receive an upfront payment of $90 million for the development of five candidate programs. Editas Medicine has the potential to earn additional payments for achieving important near-term milestones specifically related to LCA10. Allergan will have the option to license up to five programs under the agreement and will be responsible for development and commercialization of the optioned products, subject to Editas' option right to co-develop and co-promote up to two optioned products in the United States.  Editas Medicine will also be eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis.  Conference Call Information Editas Medicine and Allergan will host a conference call on Tuesday, March 14, 2016, at 4:30 p.m. ET to discuss this alliance.  To access the call, please dial (877) 809-6321 (domestic) or (615) 247-0223 (international) and provide the passcode 88272560.  A live webcast of the call will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com, and a replay will be available approximately two hours after its completion. About the CRISPR Genome Editing Technology The CRISPR technology targets specific stretches of genetic code and allows editing of DNA at precise locations in the human genome. Cas9 and Cpf1 are both enzyme/guide RNA complexes that use traditional RNA/DNA base-pairing to precisely locate specific DNA sequences with the goal of modifying or ‘editing’ a disease-associated or therapeutic genomic location. By changing the composition of the guide RNA, the Cas9 or Cpf1 nuclease complex can be reprogrammed to target different DNA sequences and can be engineered to perform a wide range of genome editing functions, including ‘cutting and removing’, ‘cutting and revising’, and ‘cutting and replacing’ genomic sequences. In this way, genome editing has the potential to treat a broad range of genetically-defined and genetically-treatable diseases. About Leber Congenital Amaurosis Leber Congenital Amaurosis, or LCA, is a group of inherited retinal dystrophies caused by mutations in at least 18 different genes. It is the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide. Symptoms of LCA appear within the first year of life, resulting in significant vision loss and blindness. The most common form of the disease, referred to as LCA10, is a monogenic disorder caused by mutations in the CEP290 gene and represents approximately 20‑30 percent of all LCA subtypes. About Allergan plc Allergan plc (:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70 mid-to-late stage pipeline programs in development. Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right. With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day. For more information, visit Allergan’s website at www.Allergan.com. About Editas Medicine Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients. Allergan Forward-Looking Statements Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Editas Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995.  The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements.  These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACTS: Allergan:Editas Medicine:Investors:Investors: Lisa DeFrancesco                    Mark Mullikin(862) 261-7152(617) 401-9083  Karina Calzadilla (862) 261- 7328     Media: Mark MarmurCristi Barnett(862) 261-7558(617) 401-0113  Dan Budwick, Pure Communications (973) 271-6085



Read more...
Jeff Auxier Invests in Gilead, Wells Fargo, Apple The guru's repeat purchases in the last 2 quarters of 2016
Jeff Auxier (Trades, Portfolio) is the manager of Auxier Focus Fund. He manages a portfolio composed of 152 stocks with a total value of $460 million. In the fourth and third quarters of 2016 the guru bought shares in the following stocks: Read more...
Jerome Dodson Adds to 9 Positions in 4th Quarter Guru's purchases involve 4 health care-related companies
Parnassus Investments founder and President Jerome Dodson (Trades, Portfolio) made no new buys in the fourth quarter, but he added to nine existing positions in his portfolio. Read more...
Weitz Funds Comments on Allergan Guru stock highlight
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be Read more...
Weekly CEO Buys Highlights Insiders purchase Aramark, Allergan, Brixmor, New Media, Pennant
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
PE Ratio 6.16
AGN's PE Ratio is ranked higher than
95% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. AGN: 6.16 )
Ranked among companies with meaningful PE Ratio only.
AGN' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 24.5 Max: 366.63
Current: 6.16
4.95
366.63
Forward PE Ratio 14.77
AGN's Forward PE Ratio is ranked higher than
63% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. AGN: 14.77 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 4.76
AGN's Price-to-Owner-Earnings is ranked higher than
94% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. AGN: 4.76 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.82  Med: 18.53 Max: 1421.16
Current: 4.76
3.82
1421.16
PB Ratio 1.24
AGN's PB Ratio is ranked higher than
82% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. AGN: 1.24 )
Ranked among companies with meaningful PB Ratio only.
AGN' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 1.24
0.87
5.9
PS Ratio 6.19
AGN's PS Ratio is ranked lower than
72% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. AGN: 6.19 )
Ranked among companies with meaningful PS Ratio only.
AGN' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 6.19
0.99
17.57
Price-to-Free-Cash-Flow 86.51
AGN's Price-to-Free-Cash-Flow is ranked lower than
87% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. AGN: 86.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 15.65 Max: 90.54
Current: 86.51
6.62
90.54
Price-to-Operating-Cash-Flow 65.96
AGN's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. AGN: 65.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.97  Med: 12.81 Max: 69.03
Current: 65.96
5.97
69.03
EV-to-EBIT -68.92
AGN's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. AGN: -68.92 )
Ranked among companies with meaningful EV-to-EBIT only.
AGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 11 Max: 104.6
Current: -68.92
-310.4
104.6
EV-to-EBITDA 20.47
AGN's EV-to-EBITDA is ranked lower than
64% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. AGN: 20.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 12.1 Max: 234.9
Current: 20.47
-224.1
234.9
Shiller PE Ratio 51.03
AGN's Shiller PE Ratio is ranked lower than
55% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. AGN: 51.03 )
Ranked among companies with meaningful Shiller PE Ratio only.
AGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.67  Med: 51.26 Max: 2115.42
Current: 51.03
14.67
2115.42
Current Ratio 2.27
AGN's Current Ratio is ranked lower than
55% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. AGN: 2.27 )
Ranked among companies with meaningful Current Ratio only.
AGN' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.56 Max: 9.8
Current: 2.27
1.03
9.8
Quick Ratio 2.18
AGN's Quick Ratio is ranked higher than
55% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. AGN: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.02 Max: 8.82
Current: 2.18
0.8
8.82
Days Inventory 139.08
AGN's Days Inventory is ranked lower than
56% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. AGN: 139.08 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 126.6 Max: 369.82
Current: 139.08
75.66
369.82
Days Sales Outstanding 61.72
AGN's Days Sales Outstanding is ranked higher than
62% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. AGN: 61.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 65.51 Max: 197.04
Current: 61.72
39.05
197.04
Days Payable 37.39
AGN's Days Payable is ranked lower than
80% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. AGN: 37.39 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 28.03  Med: 69.22 Max: 109.48
Current: 37.39
28.03
109.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.30
AGN's Dividend Yield % is ranked lower than
92% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. AGN: 0.30 )
Ranked among companies with meaningful Dividend Yield % only.
AGN' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0.32 Max: 0.63
Current: 0.3
0
0.63
Forward Dividend Yield % 1.18
AGN's Forward Dividend Yield % is ranked lower than
63% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. AGN: 1.18 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.29
AGN's 5-Year Yield-on-Cost % is ranked lower than
91% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. AGN: 0.29 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AGN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0.32 Max: 0.63
Current: 0.29
0
0.63
3-Year Average Share Buyback Ratio -29.10
AGN's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. AGN: -29.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -29.1
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.22
AGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. AGN: 1.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.21 Max: 4.68
Current: 1.22
0.6
4.68
Price-to-Median-PS-Value 3.37
AGN's Price-to-Median-PS-Value is ranked lower than
92% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. AGN: 3.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 2.32 Max: 5.54
Current: 3.37
0.67
5.54
Earnings Yield (Greenblatt) % -1.45
AGN's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. AGN: -1.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 6 Max: 12.3
Current: -1.45
1
12.3
Forward Rate of Return (Yacktman) % 11.09
AGN's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. AGN: 11.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.2  Med: 7.7 Max: 16.1
Current: 11.09
-0.2
16.1

More Statistics

Revenue (TTM) (Mil) $14,967
EPS (TTM) $ 38.35
Beta1.34
Short Percentage of Float3.37%
52-Week Range $184.50 - 261.27
Shares Outstanding (Mil)335.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 15,673 16,848 17,905
EPS ($) 16.05 18.02 20.31
EPS without NRI ($) 16.05 18.02 20.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.90%
Dividends per Share ($) 1.87 1.96 1.70
» More Articles for AGN

Headlines

Articles On GuruFocus.com
Charlie Munger: Loading Up on Leverage Apr 21 2017 
Spiros Segalas Sells American Tower, Biogen, Regeneron, Disney Apr 21 2017 
Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical D Apr 20 2017 
Allergan Partners with TARGET PharmaSolutions to Advance NASH Research Apr 20 2017 
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration Apr 18 2017 
Study These Gurus, but Don’t Buy Their Funds Apr 14 2017 
Why Charlie Munger Hates Value Investing Apr 13 2017 
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated Apr 13 2017 
Allergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experience Apr 11 2017 
Allergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S. Envi Apr 10 2017 

More From Other Websites
Trump Executive Order Could Revive Allergan-Pfizer Merger Apr 22 2017
Charlie Munger: Loading Up on Leverage Apr 21 2017
Top Analyst Upgrades and Downgrades: Costco, Domino’s Pizza, Fortinet, Verizon, Yum Brands and... Apr 21 2017
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Apr 21 2017
Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical... Apr 20 2017
Chapel Hill company partners with Allergan Apr 20 2017
Allergan Partners with TARGET PharmaSolutions to Advance NASH Research Apr 20 2017
Allergan (AGN) Collaborates with Novartis to Treat NASH Apr 19 2017
[$$] Investors bet on Incyte drug success Apr 19 2017
Allergan, Argentum settle patent dispute over eye drug Restasis Apr 18 2017
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration Apr 18 2017
A Healthcare Pick That's Moderately Shielded From Upheaval Apr 17 2017
Why Charlie Munger Hates Value Investing Apr 13 2017
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated... Apr 13 2017
The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17) Apr 12 2017
Cramer Remix: Why a slew of IPOs might not be a good thin... Apr 11 2017
Cramer's charts show these biotechs ignoring their 'polit... Apr 11 2017
Allergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common... Apr 11 2017
How Did Allergan Perform in 1Q17? Apr 10 2017
Allergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S.... Apr 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)